Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive
Andrea Nicolini1, Paola Ferrari2, Roberto Silvestri3
1Department of Oncology and New Technologies in Medicine University of Pisa Pisa Italy.
Abstract:
The era of targeted therapies has significantly advanced our understanding of cancer growth and metastasis. Intrinsic or acquired drug resistance remains a major challenge, rendering clinically overt metastatic disease incurable in most patients. This review first examines key clinical trials and their primary outcomes involving targeted therapies in the most common advanced solid tumors, along with the main mechanisms underlying drug resistance. Recently, micrometastatic disease has emerged as a novel focus of investigation aimed at definitively curing advanced solid tumors. Accordingly, this review explores the biology of micrometastases, current challenges in their detection and monitoring, and the main strategies proposed to prevent their progression. The potential roles of nanotechnology and artificial intelligence-driven predictive models are also discussed. Furthermore, we highlight specific characteristics of micrometastatic disease that favor immune modulation, and we evaluate the effectiveness of an immunotherapy regimen that inhibits immune suppression. The lead time provided by serum tumor markers, used experimentally to better track the progression of otherwise undetectable micrometastatic disease, also forms the mechanistic basis for a novel protocol we propose to prevent relapse in high-risk cancer patients. This innovative protocol holds scientific relevance being supported by an appropriate mathematical model and ready for immediate application in clinical practice.
Insights
Drug resistance limits targeted cancer therapies. This review explores micrometastatic disease, detection challenges, and novel strategies like AI and immunotherapy to prevent cancer relapse.
Area of Science:
- Oncology
- Cancer Metastasis
- Drug Resistance
Background:
- Targeted therapies have advanced cancer treatment but drug resistance remains a significant hurdle.
- Clinically overt metastatic disease is often incurable due to intrinsic or acquired resistance.
- Micrometastatic disease is a new focus for achieving cures in advanced solid tumors.
Purpose of the Study:
- To review clinical trials of targeted therapies in advanced solid tumors and their resistance mechanisms.
- To explore the biology, detection, and monitoring of micrometastases.
- To discuss strategies for preventing micrometastatic progression, including nanotechnology, AI, and immunotherapy.
Main Methods:
- Review of key clinical trials and their outcomes.
- Examination of drug resistance mechanisms in common advanced solid tumors.
- Exploration of micrometastasis biology, detection, and monitoring challenges.
- Evaluation of nanotechnology, AI-driven models, and immunotherapy for micrometastasis.
- Analysis of serum tumor markers for tracking micrometastatic disease progression.
Main Results:
- Targeted therapies show promise but face significant drug resistance.
- Micrometastatic disease presents unique challenges in detection and monitoring.
- Nanotechnology, AI, and immunotherapy offer potential strategies to combat micrometastasis.
- Serum tumor markers can track otherwise undetectable micrometastatic disease.
- A novel protocol for relapse prevention in high-risk patients is proposed.
Conclusions:
- Overcoming drug resistance is crucial for improving outcomes in advanced solid tumors.
- Early detection and intervention targeting micrometastatic disease are essential for definitive cures.
- Innovative approaches including AI, nanotechnology, and immunotherapy are key to managing micrometastasis.
- A novel, mathematically modeled protocol using serum tumor markers shows potential for preventing relapse in high-risk patients.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:18Cancer
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:15Drugs that Stabilize Microtubules